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CASE REPORTS
Case 1
This 36 year-old, right-handed female nurse presented
at the Ghent University Hospital Epilepsy Clinic
in 1997. She was one of healthy twins who had had
a normal delivery after an uneventful pregnancy. At
the age of 3 years she was diagnosed with aseptic
meningitis and made a full recovery. At the age
of 23 years she had a first episode of sudden loss
of contact, nonsense speech and shaking of both
hands. She was first treated with carbamazepine. This
was combined with valproate after 2 years. After
an unsuccessful trial with fenytoin, she was treated
with a combination of vigabatrin 2000 mg/day and
carbamazepine 1400 mg/day. At the age of 33 years
when she was first evaluated at our centre she had
at least two habitual seizures per month. She had
been on disability for over 2 years. The seizures
consistently began with a feeling of discomfort in
her head. This was followed by loss of contact,
nonsense speech, cyanosis of the lips and shaking
of the upper extremities. The whole episode would
last up to 45 seconds. Afterwards she experienced a
period of confusion of up to 15 minutes. There was
occasional secondary generalization. Family history
was negative for neurological diseases. Routine EEG
showed diffuse theta waves and focal sharp transients
in the left temporal electrodes. Prolonged video-EEG
monitoring showed an interictal spike focus with
phase reversal over the anterior temporal region (F7).
Seven habitual seizures were recorded. The semiology
was suggestive of a temporal lobe seizure origin;
ictal EEG showed left frontotemporal recruitment
of rhythmic theta activity. Optimum MRI showed
bilateral hippocampal damage. Interictal FDG-PET
showed bilateral extended areas of hypometabolism
in the temporal lobes. Neuropsychological assessment
was suggestive of bilateral medial temporal lobe dys-
function. On the basis of the pre-surgical assessment
the hypothesis was that the patient had complex partial
seizures originating in the left (medial) temporal
lobe. She subsequently underwent an intracarotid
amytal procedure which demonstrated a left-sided
hemispheric language dominance and a severe mem-
ory deficit on the right side. It was felt that the
patient was not a candidate for further evaluation since
the results of the Wada-test excluded any resective
procedure involving medial temporal lobe structures
on the left side. She was offered VNS instead.
The generator was implanted in September 1998.
The antiepileptic drug regimen was unchanged. The
surgical procedure and post-surgical follow-up were
uneventful. The generator was activated 2 weeks
after the implantation; subsequently the stimulation
output was increased by 0.25 mA increments. During
the ramping up period, the patient complained of
intermittent mild hoarseness. Three months following
the implantation when the output current reached
1.25 mA she had a single generalized tonic–clonic
seizure after 1 month of seizure freedom. The output
current was further increased to 1.5 mA with standard
stimulation parameters. The patient’s husband used
the magnet for delivering additional stimulation trains
which allowed to abort generalized seizures. During
regular follow-up with intervals of 6 weeks, the
average frequency of habitual seizures decreased from
at least two per month to less than two per 6 months.
She is again gainfully employed.
Case 2
This 26 year-old right-handed female with a history
of perinatal asphyxia developed generalized tonic–
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clonic seizures at the age of 1 year. At the age of
3 years she had daily atonic seizures and frequent
convulsions. She developed psychomotor retardation
and was admitted into a special care facility for
epileptic children for a 2-year period. There she
was treated with all available antiepileptic drugs.
Despite wearing a helmet during the daytime she
suffered frequent head trauma. At the age of 22 years,
she was treated with carbamazepine 1800 mg/day
and clobazam 10 mg/day. Video-EEG monitoring
documented daily atonic episodes, complex partial
seizures with frontal semiology, generalized convul-
sions and myoclonic jerks. The interictal EEG showed
a slow background activity with frequent slow spike
wave and polyspike complexes. During atonic and
partial seizures, the EEG showed an electrodecrement
and muscle artefacts. Neuropsychological assessment
showed an estimated IQ score of 45. Optimum
MRI showed strictly no structural abnormalities.
The clinical diagnosis of LGS was made. The
patient underwent an anterior 2/3 callosotomy in
February 1993. After the surgical procedure she
had no focal neurological deficit. She subsequently
became free of generalized convulsions and had fewer
atonic seizures. This allowed her to stop wearing
her helmet. Two years after the callosotomy, she
started having convulsive seizures again. She was
subsequently treated with lamotrigine, vigabatrin,
felbamate and clonazepam in various combinations.
In 1998 she had daily atonic seizures and frequent
states of loss of contact that lasted many hours.
The patient was again admitted to the video-EEG
monitoring unit and habitual seizures were recorded.
Based on the study of the ictal semiology of the
different seizure types and ictal EEG traces, the
diagnosis of LGs was reconfirmed. In March 1999,
an NCPTM device was implanted. Within a few
weeks during which the output current was gradually
increased to 2.75 mA, the average frequency of atonic
seizures decreased from six to one per day. The patient
became more alert and was able to manipulate the
magnet when she had the feeling that a complex partial
seizure would begin. The convulsive seizures became
rare. Temporary switching to rapid cycle stimulation
(on-time: 7 seconds; off-time: 14 seconds) failed to
further reduce the seizure frequency. She is currently
treated with lamotrigine 250 mg/day, carabamazepine
1200 mg/day and gabapentin 1200 mg/day.
Case 3
A 35 year-old right-handed female with a history
of sinusitis, common migraine and a few episodes
of severe depression requiring admission presented
with a first generalized tonic–clonic seizure at the
age of 26 years, a few days after delivering her first
and healthy newborn. EEG and computed tomog-
raphy (CT) were normal and the patient remained
untreated. At the age of 28 years she was admitted
in a regional hospital because of generalized status
epilepticus. Low-field MRI of the brain was negative.
She was treated with valproate but continued to
have episodes of loss of consciousness and aversive
movements of the head and the eyes to the left
side, followed by left-sided hemifacial twitching and
loss of speech during 60–120 seconds. At the time
of the evaluation in our institution, these episodes
occurred at least twice a month. There was occasional
secondary generalization. In the previous 3 years
she had been admitted at least four times for focal
motor status epilepticus. The patient was treated
with valproate 1000 mg/day and carbamazepine
800 mg/day. Video-EEG monitoring demonstrated
left-sided sharp transients, predominantly in the
posterior electrode contacts. The ictal semiology
suggested a right-sided frontal seizure onset; the ictal
EEG showed bilateral recruitment of sharp waves in
the parasaggital electrode positions. Optimum MRI
showed a large zone of focal cortical dysplasia without
specific signal abnormalities in the right-sided pre-
rolandic area. Interictal FDG-PET demonstrated an
area of right-sided hypometabolism in the frontal lobe.
Neuropsychological evaluation did not reveal specific
abnormalities. The patient was felt not to be a suitable
candidate for resective epilepsy surgery because of
the location and extent of the structural abnormality.
She was subsequently offered VNS. The surgical
procedure was performed in March 1995 and the
perioperative period was uneventful. The stimulation
output was gradually increased to 2.5 mA with
standard stimulation parameters. Hoarseness during
the stimulation trains required decreasing the output
to 2.25 mA. Weeks after the implantation the patient
became free of generalized convulsions; she also
stopped having loss of contact during her episodes.
The habitual seizures consisted of twitching of the
left hand and dystonic posturing during seconds to
minutes with an average frequency of one to two
per month. Use of the magnet failed to reduce
the frequency of the simple partial seizures. The
patient was further treated with a combination of
carbamazepine, phenobarbital and clonazepam. She
was able to resume her work as a housekeeper and had
a second and uneventful pregnancy. She was followed
at regular 4–6 month intervals but missed several ap-
pointments during the year 2000. In November 2000,
the patient was admitted into a regional hospital after
she had had a generalized convulsion for the first time
in 5 years. A routine check of the NCPTM device
showed an end-of-life status of the battery. In the
weeks that followed and before a new generator could
be implanted because of an administrative delay with
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the reimbursement agency, the patient became very
depressed. Mid-December 2000, a new NCPTM device
was implanted. The stimulation output was rapidly
increased to 1.75 mA. The patient was also treated
with venlafaxine, a major antidepressant, at a dose
of 37.5 mg/day. At the time of her last follow-up
visit she was again free of convulsive and complex
partial seizures but continued to have focal motor
seizures. She was able to resume most of her work
in the household. The antiepileptic drug regimen was
unchanged. The treatment with venlafaxine had been
stopped a few weeks earlier.
Self-assessment questions
Which of the following statements are true?
Question 1. The case:
(a) Despite adequate anti-epileptic treatment, 30% of patients continue to have seizures or experience
unacceptable pharmacological side effects.
(b) 50% of patients who undergo resective surgery where the epileptogenic zone can be identified become
seizure-free.
(c) Administration of new anti-epileptic drugs in candidates who are unsuitable for resective surgery will
lead to seizure freedom in a maximum of 7% of patients.
Question 2. History/anatomical basis:
(a) The first vagus nerve stimulator implanted in humans was in 1990.
(b) The left vagus nerve consists of 80% efferent fibres and about 20% afferent fibres.
(c) Afferent fibres have their origin in the nodose ganglion and primarily project to the nucleus of the
solitary tract.
(d) The nucleus of the solitary tract has widespread projections to numerous areas in the forebrain as well
as the brain stem including important areas for epileptogenesis such as the amygdala and thalamus.
(e) Heart rate is mostly influenced by the left vagus nerve.
Question 3. Mechanisms of action:
(a) In animal experiments, VNS can induce EEG synchronization, EEG desynchronization, rapid eye
movement and sleep or slow-wave sleep.
(b) VNS acts through a release of neurotransmitters and other compounds at the projection site of the vagus
nerve.
(c) c-fos studies have shown that key structures in the neuronal network are activated during VNS.
(d) Changes in supratentorial and cerebellar CBF caused by acute and chronic VNS have been
demonstrated.
Question 4. VNS and surgical procedure:
(a) VNS involves a surgical procedure where a pulse generator and a bipolar lead are implanted during a
1–2 hour operation.
(b) Once implanted the generator is switched on and stimulation is continuous.
(c) The generator can be programmed using a magnet.
(d) The patient has no control over the generator.
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Question 5. Results:
(a) Two randomised, blinded, active control trials (E03 and E05) have been conducted in a total population
of 310 with patients with refractory partial epilepsy.
(b) In the EO3 and EO5 trials, in the patients in the high stimulation group there was a mean reduction in
seizure frequency of 24% and 28% respectively.
(c) The most common treatment-related adverse events which occur during ‘on’ periods are voice
alteration, coughing, throat paraesthesia and discomfort and dyspnoea.
(d) Bradycardia and asystole are common complications during intraoperative testing.
(e) Patients treated with VNS have a higher rate of sudden unexpected unexplained death (SUDEP)
compared to patients treated with novel anti-epileptic drugs.
(f) The SUDEP rate became lower during a 2-year follow-up.
Question 6. Long-term effects and cost-benefit issues:
(a) VNS remains effective over time and there is a trend towards improved seizure control with longer use
of VNS.
(b) There are no chronic side effects with VNS.
(c) In a 5-year follow-up, 44% of patients reported a large reduction in seizure frequency and severity.
(d) There is no change in the epilepsy-related direct medical costs after implantation with the vagus nerve
stimulator.
(e) The battery life of the generator is estimated to be 8 years.
(f) In a comparative study of conservative treatment, resective epilepsy surgery and VNS, VNS was
demonstrated to have favourable cost efficacy in patients who were unsuitable candidates for resective
surgery.
Answers
Question 1. The case:
(a) true.
(b) false—60–90% of patients who undergo resective surgery where the epileptogenic zone can be
identified become seizure-free.
(c) true.
Question 2. History/anatomical basis:
(a) false—the first vagus nerve stimulator implanted in humans was in 1988.
(b) false—the left vagus nerve consists of about 80% afferent fibres and about 20% efferent fibres.
(c) true.
(d) true.
(e) false—heart rate is mostly influenced by the right vagus nerve.
Question 3. Mechanisms of action:
(a) true—depending on the level of anaesthesia and the stimulus parameters used.
(b) unsure—while there have been studies showing changes in amino-acid and neurotransmitter metabolite
concentrations in CSF samples before and after VNS, it remains to be clarified whether these findings
are epiphenomena or directly related to VNS.
(c) true.
(d) true.
460 P. Boon et al.
Question 4. VNS and surgical procedure:
(a) true.
(b) false—stimulation can be initiated immediately after the surgery or after the patient has fully recovered
from the surgery, typically 1–2 weeks later.
(c) false—the generator is programmed with a radio frequency telemetry wand connected to an IBM
compatible computer.
(d) false—the patient/carer can use the magnet to deliver additional stimulation in case of an aura or seizure
or if kept over the generator the magnet will inhibit the stimulation.
Question 5. Results:
(a) true.
(b) true.
(c) true.
(d) false—bradycardia and asystole have been reported as rare complications during intraoperative testing,
probably due to stimulation of the cervical cardiac branches of the vagus nerve either directly or by
collateral current spread.
(e) false—patients treated with VNS have a comparable rate of sudden unexpected unexplained death
compared with patients treated with novel anti-epileptic drugs.
(f) true.
Question 6. Long-term effects and cost-benefit issues:
(a) true.
(b) false—chronic side effects were identical to those observed during the randomized trials.
(c) true.
(d) false—a study showed that there is a significant decrease in epilepsy-related direct medical costs after
implantation.
(e) true.
(f) true.
